Diabetes drug slows kidney disease – study

By | April 15, 2019

Doctors say it’s hard to overstate the importance of this study, and what it means for curbing this problem, which is growing because of the obesity epidemic.

The study tested the drug Invokana. Results were discussed at a medical meeting in Australia and published by the New England Journal of Medicine.

More than 420 million people worldwide have diabetes, and most cases are Type 2, the kind tied to obesity. It occurs when the body can’t make enough or properly use insulin, which turns food into energy.

This can damage the kidneys over time, causing disease and ultimately, failure. In the US, it’s responsible for nearly half-a-million people needing dialysis, and for thousands of kidney transplants each year.

Some blood pressure drugs lower this risk but they’re only partially effective.

The new study tested Invokana, a daily pill sold now to help control blood sugar, to see if it also could help prevent kidney disease when added to standard treatments.

For the study, about 13,000 people with Type 2 diabetes and chronic kidney disease from around the world were to be given Invokana or dummy pills. Independent monitors stopped the study early, after 4,400 people had been treated for about 2.5 years on average, when it was clear the drug was helping.

Read More:  Protecting those on the frontline from Ebola

Those on the drug had a 30 per cent lower risk of one of these problems – kidney failure, need for dialysis, need for a kidney transplant, death from kidney- or heart-related causes, or other signs that kidneys were failing.

For every 1,000 people taking the drug for 2.5 years, there would be 47 fewer cases of one of these problems, researchers estimate.

Australian Associated Press

Western Advocate – Health